Skip to Content

Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO data Presented at the European Atherosclerosis Society 2012 Meeting

CARLSBAD, Calif., May 23 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

 Data from KYNAMRO™ presented at EAS 2012

 Friday, June 1st at 12:00 p.m. ET / 9:00 a.m. PT


 Live on the Internet.  Simply log onto our Web site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at


Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at .

SOURCE Isis Pharmaceuticals, Inc.

CONTACT: Kristina Lemonidis, Director, Corporate Communications, +1-760-603-2490, or Amy Blackley, Ph.D., Assistant Director, Corporate Communications, +1-760-603-2772

Web Site:


Posted: May 2012

View comments